Evidence map›Paper›PMID 34070429›Full record

ArticleCells2021

Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells.

Sarah Thomas Broome, Teagan Fisher, Alen Faiz, Kevin A Keay, Giuseppe Musumeci, Ghaith Al-Badri, Alessandro Castorina

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sarah Thomas BroomeLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Teagan FisherLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Alen FaizRespiratory Bioinformatics and Molecular Biology (RBMB) Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Kevin A KeayLaboratory of Neural Structure and Function (LNSF), School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0003-3934-4380
Giuseppe MusumeciSection of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, via S. Sofia, 87, 95123 Catania, Italy.ORCID 0000-0002-8260-8890
Ghaith Al-BadriLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0003-3342-2376
Alessandro CastorinaLaboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0001-7037-759X
University of Technology Sydney · AUThe University of Sydney · AUUniversity of Catania · IT

Funding

University of Technology Sydney Start-up Research Fund 2018 n/aUTS Seed Fund 2020 n/a
6 · The paper itself

Abstract

Buspirone is an anxiolytic drug with robust serotonin receptor 1A (Htr1a) agonist activities. However, evidence has demonstrated that this drug also targets the dopamine D3 receptor (Drd3), where it acts as a potent antagonist. In vivo, Drd3 blockade is neuroprotective and reduces inflammation in models of Parkinson's disease. To test if buspirone also elicited anti-inflammatory activities in vitro, we generated stable Drd3

Indexed as

AnimalsAnti-Inflammatory AgentsBuspironeCell LineInflammationMiceMicrogliaReceptors, Dopamine D3Receptor, Serotonin, 5-HT1AAnti-Inflammatory AgentsBuspironeDrd3 protein, mouseHtr1a protein, mouseReceptors, Dopamine D3Receptor, Serotonin, 5-HT1A5-hydroxytryptamine 1a receptordopamine D3 receptormicroglianeuroinflammationParkinson’s disease

Identifiers

PMID34070429
PMCPMC8229595
OpenAlexW3164994963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.